68 results
Page 2 of 4
6-K/A
EX-99.1
t9tf54nly7
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
o1pq6
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.3
h9m69 o45q
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
etpmoh c93c
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
6j21bd
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
hre t9xmol5wq1uies3f
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
lz1tbim 4i
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.3
nv0et2gwz1g
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
5nrswoh34qp2c1
11 Jul 22
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
4:05pm
6-K
EX-99.1
0dwgyuflev r1jb3
27 Jun 22
Current report (foreign)
4:05pm
6-K
EX-99.1
335dfdl iip9l
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
6e7si
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.1
xwavniit6kw
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
xwb0iuekipz7jwh
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
424B7
ybdzje64 rogucw3
5 May 22
Prospectus with selling stockholder info
12:00am
6-K
EX-99.1
kzcsx5pva1lyz6u 268
14 Apr 22
Current report (foreign)
4:11pm
F-3ASR
u2u1 tnkzb2g
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
6-K
EX-99.1
xi6 leabf0
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
kz3lfm8d0xzvlt
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am